ABC has been the topic of several other research reports. JPMorgan Chase & Co. raised their price target on shares of Abcam from GBX 864 ($11.55) to GBX 946 ($12.65) and gave the company a neutral rating in a report on Monday, September 18th. Peel Hunt raised their price target on shares of Abcam from GBX 750 ($10.03) to GBX 1,020 ($13.64) and gave the company a hold rating in a report on Wednesday, September 20th. Panmure Gordon restated a sell rating on shares of Abcam in a report on Monday, September 11th. Finally, Berenberg Bank restated a buy rating and issued a GBX 1,100 ($14.71) price target on shares of Abcam in a report on Monday, September 11th. One analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of GBX 996 ($13.32).
Abcam (ABC) opened at GBX 1,089 ($14.56) on Friday. Abcam has a 1-year low of GBX 9.73 ($0.13) and a 1-year high of GBX 1,113 ($14.88). The firm has a market cap of $2,230.00 and a PE ratio of 5,185.71.
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.
What are top analysts saying about Abcam? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Abcam and related companies.